MRSNMersana Therapeutics, Inc.

MRSN Stock Price, Valuation & Chart | Mersana Therapeutics, Inc.

Compare

$29.080+0.00 (+0.00%)

At close · 06 Jan 2026, 09:00 pm

Sector: Healthcare Industry: Biotechnology MRSN intrinsic value MRSN calculated fair value vs price

Overview Financials Dividends Ratios

MRSN Historical price chart

MRSN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization145.36M

PE Ratio-2.08

EPS-13.95

Trading Volume624.02K

Today's High/Low29.08/28.78

Dividend Yield0.00

52 Week High/Low30.39/5.21

Shares Outstanding5.00M

MRSN Financial Statement

MRSN Analyst ratings

MRSN Analysis & performance metrics

MRSN Company profile

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a…

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted…

MRSN Management team

Name

Position

Mohan Bala Ph.D.

Senior Vice President & Chief Development Officer

Ashish Mandelia

Vice President & Chief Accounting Officer

Brian C. DeSchuytnerCFO

Senior Vice President, Chief Financial Officer & Chief Operating Officer

Martin H. Huber M.D.CEO

President, Chief Executive Officer & Director

Alejandra Veronica Carvajal J.D.

Senior Vice President, Secretary & Chief Legal Officer

Jason Fredette

Senior Vice President of Investor Relations & Corporate Communications

Mikhail Papisov Ph.D.

Co-Founder

Chuck Miller

Senior Vice President of Regulatory Affairs

Name

Position

Mohan Bala Ph.D.

Senior Vice President & Chief Development Officer

Ashish Mandelia

Vice President & Chief Accounting Officer

Brian C. DeSchuytnerCFO

Senior Vice President, Chief Financial Officer & Chief Operating Officer

Martin H. Huber M.D.CEO

President, Chief Executive Officer & Director

Alejandra Veronica Carvajal J.D.

Senior Vice President, Secretary & Chief Legal Officer

Jason Fredette

Senior Vice President of Investor Relations & Corporate Communications

Mikhail Papisov Ph.D.

Co-Founder

Chuck Miller

Senior Vice President of Regulatory Affairs

Management Team

Mohan Bala Ph.D.

Senior Vice President & Chief Development Officer

Ashish Mandelia

Vice President & Chief Accounting Officer

Brian C. DeSchuytnerCFO

Senior Vice President, Chief Financial Officer & Chief Operating Officer

Martin H. Huber M.D.CEO

President, Chief Executive Officer & Director

Alejandra Veronica Carvajal J.D.

Senior Vice President, Secretary & Chief Legal Officer

Jason Fredette

Senior Vice President of Investor Relations & Corporate Communications

Mikhail Papisov Ph.D.

Co-Founder

Chuck Miller

Senior Vice President of Regulatory Affairs

Management

Mohan Bala Ph.D.

Senior Vice President & Chief Development Officer

Ashish Mandelia

Vice President & Chief Accounting Officer

Brian C. DeSchuytnerCFO

Senior Vice President, Chief Financial Officer & Chief Operating Officer

Martin H. Huber M.D.CEO

President, Chief Executive Officer & Director

Alejandra Veronica Carvajal J.D.

Senior Vice President, Secretary & Chief Legal Officer

Jason Fredette

Senior Vice President of Investor Relations & Corporate Communications

Mikhail Papisov Ph.D.

Co-Founder

Chuck Miller

Senior Vice President of Regulatory Affairs

Total 8 executives

MRSN Frequently asked questions

What is Mersana Therapeutics, Inc. (MRSN) Stock Price?

Current stock price of Mersana Therapeutics, Inc. (MRSN) stock is $29.080. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Mersana Therapeutics, Inc. (MRSN) stock is 624.02K.

Last updated at 06 Jan 2026, 09:00 pm.

Why is the Mersana Therapeutics, Inc. (MRSN) stock price going up or down today?

The stock price of Mersana Therapeutics, Inc. (MRSN) can change with earnings, company news, and overall market sentiment. Mersana Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Mersana Therapeutics, Inc. stock expensive at its current price?

Whether Mersana Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MRSN on this page is -2.08. EPS on this page is -13.95. Compare those figures with peers and growth expectations before deciding if the current Mersana Therapeutics, Inc. price is justified.

How has the stock price of Mersana Therapeutics, Inc. (MRSN) performed historically?

Historical performance for Mersana Therapeutics, Inc. (MRSN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MRSN reacted to past earnings and market events.

Should I buy Mersana Therapeutics, Inc. (MRSN) stock, at this price?

Buying Mersana Therapeutics, Inc. (MRSN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.